Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 26, 2004. The report details a series of share repurchase transactions executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Share Repurchases: The Company purchased a total of 3,050,000 Ordinary shares of 25 pence each between November 24 and November 26, 2004.
- Transaction Prices: Shares were purchased at prices ranging from 1,119.4807 pence to 1,133.8257 pence per share.
- Treasury Holdings: Following the final transaction on November 26, the Company holds 57,078,000 shares in Treasury.
- Shares in Issue: Excluding Treasury shares, there are 5,879,865,055 shares in issue as of November 26, 2004.
Material Changes
The primary material change reported is the reduction in the number of shares in issue and the increase in Treasury shares due to the repurchase program. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the total cost of the 3,050,000 shares repurchased based on the disclosed per-share prices.
- Confirm the updated total share count (5,879,865,055) in subsequent filings or market data.
- Review the remaining authority for share repurchases under the May 17, 2004 shareholder mandate.
- Check for any impact on earnings per share (EPS) resulting from the reduced share count in upcoming financial reports.